Cargando…

Variability within rare cell states enables multiple paths towards drug resistance

Molecular differences between individual cells can lead to dramatic differences in cell fate, such as death versus survival of cancer cells upon drug treatment. These originating differences remain largely hidden due to difficulties in determining precisely what variable molecular features lead to w...

Descripción completa

Detalles Bibliográficos
Autores principales: Emert, Benjamin L., Cote, Christopher, Torre, Eduardo A., Dardani, Ian P., Jiang, Connie L., Jain, Naveen, Shaffer, Sydney M., Raj, Arjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277666/
https://www.ncbi.nlm.nih.gov/pubmed/33619394
http://dx.doi.org/10.1038/s41587-021-00837-3
_version_ 1783722121377087488
author Emert, Benjamin L.
Cote, Christopher
Torre, Eduardo A.
Dardani, Ian P.
Jiang, Connie L.
Jain, Naveen
Shaffer, Sydney M.
Raj, Arjun
author_facet Emert, Benjamin L.
Cote, Christopher
Torre, Eduardo A.
Dardani, Ian P.
Jiang, Connie L.
Jain, Naveen
Shaffer, Sydney M.
Raj, Arjun
author_sort Emert, Benjamin L.
collection PubMed
description Molecular differences between individual cells can lead to dramatic differences in cell fate, such as death versus survival of cancer cells upon drug treatment. These originating differences remain largely hidden due to difficulties in determining precisely what variable molecular features lead to which cellular fates. Thus, we developed Rewind, a methodology that combines genetic barcoding with RNA FISH to directly capture rare cells that give rise to cellular behaviors of interest. Applied to BRAF(V600E) melanoma, we trace drug-resistant cell fates back to single-cell gene expression differences in their drug-naive precursors (initial frequency of ~1:1000–1:10,000 cells) and relative persistence of MAP-kinase signaling soon after drug treatment. Within this rare subpopulation, we uncover a rich substructure in which molecular differences between several distinct subpopulations predict future differences in phenotypic behavior, such as proliferative capacity of distinct resistant clones following drug treatment. Our results reveal hidden, rare-cell variability that underlies a range of latent phenotypic outcomes upon drug exposure.
format Online
Article
Text
id pubmed-8277666
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-82776662021-08-22 Variability within rare cell states enables multiple paths towards drug resistance Emert, Benjamin L. Cote, Christopher Torre, Eduardo A. Dardani, Ian P. Jiang, Connie L. Jain, Naveen Shaffer, Sydney M. Raj, Arjun Nat Biotechnol Article Molecular differences between individual cells can lead to dramatic differences in cell fate, such as death versus survival of cancer cells upon drug treatment. These originating differences remain largely hidden due to difficulties in determining precisely what variable molecular features lead to which cellular fates. Thus, we developed Rewind, a methodology that combines genetic barcoding with RNA FISH to directly capture rare cells that give rise to cellular behaviors of interest. Applied to BRAF(V600E) melanoma, we trace drug-resistant cell fates back to single-cell gene expression differences in their drug-naive precursors (initial frequency of ~1:1000–1:10,000 cells) and relative persistence of MAP-kinase signaling soon after drug treatment. Within this rare subpopulation, we uncover a rich substructure in which molecular differences between several distinct subpopulations predict future differences in phenotypic behavior, such as proliferative capacity of distinct resistant clones following drug treatment. Our results reveal hidden, rare-cell variability that underlies a range of latent phenotypic outcomes upon drug exposure. 2021-02-22 2021-07 /pmc/articles/PMC8277666/ /pubmed/33619394 http://dx.doi.org/10.1038/s41587-021-00837-3 Text en http://www.nature.com/authors/editorial_policies/license.html#termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Emert, Benjamin L.
Cote, Christopher
Torre, Eduardo A.
Dardani, Ian P.
Jiang, Connie L.
Jain, Naveen
Shaffer, Sydney M.
Raj, Arjun
Variability within rare cell states enables multiple paths towards drug resistance
title Variability within rare cell states enables multiple paths towards drug resistance
title_full Variability within rare cell states enables multiple paths towards drug resistance
title_fullStr Variability within rare cell states enables multiple paths towards drug resistance
title_full_unstemmed Variability within rare cell states enables multiple paths towards drug resistance
title_short Variability within rare cell states enables multiple paths towards drug resistance
title_sort variability within rare cell states enables multiple paths towards drug resistance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277666/
https://www.ncbi.nlm.nih.gov/pubmed/33619394
http://dx.doi.org/10.1038/s41587-021-00837-3
work_keys_str_mv AT emertbenjaminl variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT cotechristopher variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT torreeduardoa variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT dardaniianp variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT jiangconniel variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT jainnaveen variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT shaffersydneym variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance
AT rajarjun variabilitywithinrarecellstatesenablesmultiplepathstowardsdrugresistance